Forecast
The analysts' average price target is €4.56 (+178.05%). The median is €4.56 (+178.05%).
| Buy |
Â
4 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Eledon applies to FDA for Tegoprubart indication in islet cell transplantation
Eledon has filed an investigational new drug (IND) application with the FDA for a registration‑enabling study of the anti‑CD40L antibody Tegoprubart for immunosuppression in islet cell transplants for type 1 diabetes. The study would be Eledon’s first company‑sponsored trial in this area; investigator‑initiated studies are already underway at UChicago, Duke and MGH, and compassionate‑use treatments are also being provided. Earlier results in 12 treated patients showed insulin independence, HbA1c <7.0% and stable graft function for up to 22 months; Eledon also plans to start the global phase‑3 LEGACY study in kidney transplantation in Q4 2026 with about 600 patients. » More on de.investing.com
Eledon Pharmaceuticals presents phase‑2 results and plans phase‑3 alignment with FDA
At the Leerink conference, Eledon Pharmaceuticals presented data on tegoprubart in kidney transplants, showing non‑inferiority to tacrolimus and a better safety profile, but no statistically significant superiority in kidney function. The company plans to finalize the phase‑3 study design with the FDA by year‑end and aims to start the trial within the year. Eledon received orphan‑drug designation for liver transplantation, is planning a liver‑related investigator‑sponsored trial (IST), and is evaluating expansion and strategic partnerships in islet‑cell transplantation. Cash on hand exceeds $130 million, providing a runway into the second quarter of next year. » More on de.investing.com
Eledon Pharmaceuticals plans phase‑3 for Tegoprubart despite missed endpoints
At the Guggenheim Summit Eledon Pharmaceuticals said Tegoprubart showed significant safety advantages in kidney transplant studies, but the phase‑2 BESTOW trial missed its primary endpoint for renal function. The company plans to start a registrational phase‑3 trial with a composite endpoint by the end of 2026 and intends to place greater emphasis on patient‑reported outcomes. Positive early results in islet‑cell transplantation are to be advanced into a sponsored study in 2026, with an IND filing planned by year‑end. Eledon has funding into the second quarter of 2027 and is also pursuing global collaborations in xenotransplantation. » More on de.investing.com
Eledon: 24-month data on tegoprubart show improved kidney function and no rejections
Eledon presented 24-month follow-up data from eight patients in the phase‑1b study of tegoprubart in kidney transplantation. Mean eGFR increased from 67.0 ml/min/1.73 m² at 12 months to 74.2 ml/min/1.73 m² at 24 months; there were no biopsy‑confirmed acute rejection episodes, graft losses, deaths, new-onset diabetes, or donor-specific antibodies reported. Tegoprubart is an anti‑CD40L antibody being investigated as a non‑lymphocyte‑depleting immunomodulatory therapy. Financials show a solid balance sheet with a high current ratio and more cash than debt, providing runway for the clinical programs. » More on de.investing.com
Eledon Pharmaceuticals stock rises after positive Tegoprubart data on islet cell transplantation
Eledon Pharmaceuticals’ stock climbed about 3.3% in after-hours trading following preliminary study results for Tegoprubart in type 1 diabetes. In the ongoing University of Chicago Medicine trial, all six initial patients achieved insulin independence after one or two islet cell transplants, some for more than a year, accompanied by low HbA1c levels. Tegoprubart was well tolerated with no serious infections, thromboembolic events, rejection, or signs of kidney or neurological toxicity. The study has been expanded to 12 participants and is funded by Breakthrough T1D, which also plans to support a second study in patients with chronic kidney disease. » More on de.investing.com
Financials
In the last quarter, Eledon Pharmaceuticals had revenue of €0 and net profit of -€3.47M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -3.47M | 76.66% |
| EBITDA | -3.47M | 76.66% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €146.25M |
Number of shares | 84.46M |
52-week high/low | €4.09 - €1.23 |
| Dividends | No |
Beta | 0.85 |
P/E ratio | -2.41 |
PEG ratio | 0.17 |
P/B ratio | 3.12 |
P/S ratio | 0.00 |
Company profile
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Name | Eledon Pharmaceuticals |
| CEO | David-Alexandre C. Gros |
| Headquarters | Irvine,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 09/17/2014 |
| Employees | 33 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ELDN |
Frankfurt | 2TK.F |
MĂĽnchen | 2TK.MU |
DĂĽsseldorf | 2TK.DU |